Lumbar degenerative disease
Conditions
Interventions
Multimodal Analgesia Experimental Group:1 hour before induction of anesthesia, oral celecoxib capsules 200 mg, pregabalin capsules 150 mg
Before the end of the operation, use ropivacaine injection 20ml: 150mg for local infiltration anesthesia at the operating area or screw entry site
After the patient was awake from anesthesia, he was intravenously infus
Patient controlled analgesia control group:After the patient is awake from anesthesia, a patient-controlled analgesia pump is placed intravenously, prepared with 100ug sufentanil citrate, 10mg tropise
Sponsors
Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) The diagnosis of lumbar degenerative disease is clear, which seriously affects work and life. After strict conservative treatment, it is ineffective for 3-6 months. Surgical treatment is required, and there is no obvious surgical contraindication; (2) Symptoms, signs and imaging studies of lumbar degenerative disease are consistent; (3) The range of responsible lesions for lumbar degeneration is L2-L5; (4) The age of the patient is greater than 18 years; (5) The patient agrees to undergo oblique lateral lumbar interbody fusion and signs the surgical consent form.
Exclusion criteria
Exclusion criteria: (1) Degree III and IV lumbar spondylolisthesis; (2) Developmental spinal stenosis; (3) Severe osteoporosis; (4) Moderate to severe spinal deformity; (5) Obvious deformity of the extreme lateral side of the left iliac vein, which hinders the operation of the oblique lateral area of the L4/5 intervertebral disc; (6) A history of previous abdominal surgery, large scar formation in the left retroperitoneum area; (7) Infectious diseases such as spinal tuberculosis; (8) Those who have other serious liver, kidney, cardiovascular, blood system diseases, etc., are not recommended to use non-steroidal drugs after consultation with relevant departments; (9) Patients with active gastroduodenal ulcer; (10) Celecoxib should not be used for those allergic to sulfa drugs; (11) Patients who have been using analgesics for a long time before the operation and the time of withdrawal is less than 3 days; (12) Pregnant or lactating patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Early postoperative pain score; | — |
Secondary
| Measure | Time frame |
|---|---|
| The total number of PCA compressions, the total amount of drugs used in PCA, and additional remedial analgesia;Analgesia costs and length of hospital stay; | — |
Countries
China
Contacts
Public ContactWei Hu
Second Department of Spine, Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine
Outcome results
None listed